Table 8.
Selected first-line treatment studies in unfit patients.
| Author, year | Phase, N | Patient profile | ORR (%) | Median PFS (months) | Median OS (months) |
|---|---|---|---|---|---|
| Doxorubicin–gemcitabine → paclitaxel–carboplatin | |||||
| Galsky, 2007 [83] | II; 25 | CrCl <60 ml/min and/or prior nephrectomy | 56 | NR | 15 |
| Bevacizumab + gemcitabine–carboplatin → bevacizumab | |||||
| Balar, 2013 [84] | II; 51 | CrCl <60 ml/min and/or solitary kidney and/or KPS 60–70% | 43 | 6.5 | 13.9 |
| Gemcitabine | |||||
| Culine, 2011 [82] | R II; 21 | CrCl 30–60 ml/min and/or PS 2 | 43 | 3.8 | 5.4 |
| Sunitinib | |||||
| Bellmunt, 2011 [85] | II; 38 | CrCl 30–60 ml/min (PS 0–1) | 8 | 4.8 | 8.1 |
KPS, Karnofsky performance status; PFS, progression-free survival; ORR, overall response rate; CrCl, creatinine clearance; OS, overall survival; NR, not reported; UC, urothelial carcinoma.